[1] M. Avissar, B.C. Christensen, K.T. Kelsey, et al., MicroRNA expression ratio is predictive of head and neck squamous cell carcinoma, Clin Cancer Res. 15 (2009) 2850-2855.https://doi.org/10.1158/1078-0432.CCR-08-3131
[2] B. Allen, A. Schneider, B. Victoria, et al., Blood Serum From Head and Neck Squamous Cell Carcinoma Patients Induces Altered MicroRNA and Target Gene Expression Profile in Treated Cells, Frontiers in oncology. 8 (2018) 217.https://doi.org/10.3389/fonc.2018.00217
[3] C. Peitzsch, J. Nathansen, S.I. Schniewind, et al., Cancer Stem Cells in Head and Neck Squamous Cell Carcinoma: Identification, Characterization and Clinical Implications, Cancers (Basel). 11 (2019) 616.https://doi.org/10.3390/cancers11050616
[4] S. Ausoni, P. Boscolo-Rizzo, B. Singh, et al., Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives, Cancer and Metastasis Reviews. 35 (2016) 413-426.https://doi.org/10.1007/s10555-016-9625-1
[5] E.L. Britt, S. Raman, K. Leek, et al., Combination of fenretinide and ABT-263 induces apoptosis through NOXA for head and neck squamous cell carcinoma treatment, PLos One. 14 (2019) e0219398.https://doi.org/10.1371/journal.pone.0219398
[6] K. Koole, M.J. Clausen, R.J. van Es, et al., FGFR Family Members Protein Expression as Prognostic Markers in Oral Cavity and Oropharyngeal Squamous Cell Carcinoma, Molecular diagnosis
therapy. 20 (2016) 363-374.https://doi.org/10.1007/s40291-016-0204-5
[7] X.X. Tang, J. He, B. Li, et al., Efficacy and Safety of Gefitinib in Patients with Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials, Journal of oncology. 2019 (2019) 6273438.https://doi.org/10.1155/2019/6273438
[8] W. Cao, J. Liu, R. Xia, et al., X-linked FHL1 as a novel therapeutic target for head and neck squamous cell carcinoma, Oncotarget. 7 (2016) 14537-14550.https://doi.org/10.18632/oncotarget.7478
[9] P. Ahmad, J. Sana, M. Slavik, et al., MicroRNAs Involvement in Radioresistance of Head and Neck Cancer, Dis Markers. 2017 (2017) 8245345.https://doi.org/10.1155/2017/8245345
[10] E. Orosz, K. Gombos, T. Riedling, et al., Comparative miRNA Expression Profile Analysis of Squamous Cell Carcinoma and Peritumoral Mucosa from the Meso- and Hypopharynx, Cancer Genomics Proteomics. 14 (2017) 285-292.https://doi.org/10.21873/cgp.20039
[11] R. Qureshi, A. Sacan, A novel method for the normalization of microRNA RT-PCR data, BMC Med Genomics. 6 Suppl 1 (2013) S14.https://doi.org/10.1186/1755-8794-6-S1-S14
[12] S. Irani, miRNAs Signature in Head and Neck Squamous Cell Carcinoma Metastasis: A Literature Review, Journal of dentistry. 17 (2016) 13.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/27284551/
[13] H. Wang, Y. Tang, D. Yang, et al., MicroRNA-591 Functions as a Tumor Suppressor in Hepatocellular Carcinoma by Lowering Drug Resistance through Inhibition of Far-Upstream Element-Binding Protein 2-Mediated Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Axis, Pharmacology (2019) 1-14.https://doi.org/10.1159/000501162
[14] S. Hussein, H. Mosaad, H.E. Rashed, et al., Up-regulated miR-221 expression as a molecular diagnostic marker in laryngeal squamous cell carcinoma and its correlation with Apaf-1 expression, Cancer Biomark. 19 (2017) 279-287.https://doi.org/10.3233/CBM-160444
[15] L. Zhou, F. Jiang, X. Chen, et al., Downregulation of miR-221/222 by a microRNA sponge promotes apoptosis in oral squamous cell carcinoma cells through upregulation of PTEN, Oncol Lett. 12 (2016) 4419-4426.https://doi.org/10.3892/ol.2016.5250
[16] X. Deng, L. Ma, M. Wu, et al., miR-124 radiosensitizes human glioma cells by targeting CDK4, J Neurooncol. 114 (2013) 263-274.https://doi.org/10.1007/s11060-013-1179-2
[17] C. Rippe, M. Blimline, K.A. Magerko, et al., MicroRNA changes in human arterial endothelial cells with senescence: relation to apoptosis, eNOS and inflammation, Exp Gerontol. 47 (2012) 45-51.https://doi.org/10.1016/j.exger.2011.10.004
[18] J.K. Gillies, I.A. Lorimer, Regulation of p27Kip1 by miRNA 221/222 in glioblastoma, Cell Cycle. 6 (2007) 2005-2009.https://doi.org/10.4161/cc.6.16.4526
[19] F. Felicetti, M.C. Errico, L. Bottero, et al., The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms, Cancer Res. 68 (2008) 2745-2754.https://doi.org/10.1158/0008-5472.CAN-07-2538
[20] S. Ambs, R.L. Prueitt, M. Yi, et al., Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer, Cancer Res. 68 (2008) 6162-6170.https://doi.org/10.1158/0008-5472.CAN-08-0144
[21] J. Li, Y. Wang, W. Yu, et al., Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance, Biochem Biophys Res Commun. 406 (2011) 70-73.https://doi.org/10.1016/j.bbrc.2011.01.111
[22] S. Ergun, K. Arman, E. Temiz, et al., Expression patterns of miR-221 and its target Caspase-3 in different cancer cell lines, Mol Biol Rep. 41 (2014) 5877-5881.https://doi.org/10.1007/s11033-014-3461-6
[23] A.I. Wald, E.E. Hoskins, S.I. Wells, et al., Alteration of microRNA profiles in squamous cell carcinoma of the head and neck cell lines by human papillomavirus, Head Neck. 33 (2011) 504-512.https://onlinelibrary.wiley.com/doi/abs/10.1002/hed.21475
[24] C.J. Yang, W.G. Shen, C.J. Liu, et al., miR-221 and miR-222 expression increased the growth and tumorigenesis of oral carcinoma cells, J Oral Pathol Med. 40 (2011) 560-566.https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1600-0714.2010.01005.x
[25] C.J. Liu, S.Y. Kao, H.F. Tu, et al., Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer, Oral Dis. 16 (2010) 360-364.https://doi.org/10.1111/j.1601-0825.2009.01646.x
[26] T.S. Wong, X.B. Liu, B.Y. Wong, et al., Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue, Clin Cancer Res. 14 (2008) 2588-2592.https://doi.org/10.1158/1078-0432.CCR-07-0666
[27] M. Ashburner, C.A. Ball, J.A. Blake, et al., Gene ontology: tool for the unification of biology. The Gene Ontology Consortium, Nat Genet. 25 (2000) 25-29.https://doi.org/10.1038/75556
[28] M. Kanehisa, S. Goto, Y. Sato, et al., KEGG for integration and interpretation of large-scale molecular data sets, Nucleic Acids Res. 40 (2012) D109-114.https://doi.org/10.1093/nar/gkr988
[29] D.S. Chandrashekar, B. Bashel, S.A.H. Balasubramanya, et al., UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses, Neoplasia. 19 (2017) 649-658.https://doi.org/10.1016/j.neo.2017.05.002
[30] S.V. Vasaikar, P. Straub, J. Wang, et al., LinkedOmics: analyzing multi-omics data within and across 32 cancer types, Nucleic Acids Res. 46 (2018) D956-d963.https://doi.org/10.1093/nar/gkx1090
[31] Z. Cheng, D. Xing, Ginsenoside Rg3 inhibits growth and epithelial-mesenchymal transition of human oral squamous carcinoma cells by down-regulating miR-221, Eur J Pharmacol. 853 (2019) 353-363.https://doi.org/10.1016/j.ejphar.2019.03.040
[32] H. Dweep, N. Gretz, miRWalk2.0: a comprehensive atlas of microRNA-target interactions, Nat Methods. 12 (2015) 697.https://doi.org/10.1038/nmeth.3485
[33] L.P. Wang, W.H. Chen, J. Zha, et al., miR543 acts as a novel oncogene in oral squamous cell carcinoma by targeting CYP3A5, Oncol Rep. 42 (2019) 973-990.https://doi.org/10.3892/or.2019.7230
[34] M. Ruwali, A. Dhawan, M.C. Pant, et al., Clinical Management of Head and Neck Cancer Cases: Role of Pharmacogenetics of CYP2 and GSTs, Oncol Res Treat. 39 (2016) 221-226.https://doi.org/10.1159/000444608
[35] N. Xu, Y.-P. Wu, Z.-B. Ke, et al., Identification of key DNA methylation-driven genes in prostate adenocarcinoma: an integrative analysis of TCGA methylation data, Journal of Translational Medicine. 17 (2019).https://doi.org/10.1186/s12967-019-2065-2
[36] L. Yilmaz, E. Borazan, T. Aytekin, et al., Increased UGT1A3 and UGT1A7 Expression is Associated with Pancreatic Cancer, Asian Pacific Journal of Cancer Prevention. 16 (2015) 1651-1655.https://doi.org/10.7314/apjcp.2015.16.4.1651
[37] B. Cengiz, O. Yumrutas, E. Bozgeyik, et al., Differential expression of the UGT1A family of genes in stomach cancer tissues, Tumor Biology. 36 (2015) 5831-5837.https://link.springer.com/article/10.1007%2Fs13277-015-3253-1
[38] W. Chen, W. Fu, Q. Deng, et al., Multiple metals exposure and chromosome damage: Exploring the mediation effects of microRNAs and their potentials in lung carcinogenesis, Environ Int. 122 (2019) 291-300.https://linkinghub.elsevier.com/retrieve/pii/S0160412018320919
[39] X.T. Dong, Y.D. Liu, Expression and significance of miR-24 and miR-101 in patients with advanced gastric cancer, Oncol Lett. 16 (2018) 5769-5774.https://doi.org/10.3892/ol.2018.9324
[40] F.F. Jin, R. Yang, Y. Wei, et al., HIF-1alpha-induced miR-23a approximately 27a approximately 24 cluster promotes colorectal cancer progression via reprogramming metabolism, Cancer Lett. 440-441 (2019) 211-222.https://doi.org/10.1016/j.canlet.2018.10.025
[41] P.Y. Jing, N. Zhao, N.L. Xie, et al., miR-24-3p/FGFR3 Signaling as a Novel Axis Is Involved in Epithelial-Mesenchymal Transition and Regulates Lung Adenocarcinoma Progression, J Immunol Res. 2018 (2018) 2834109.https://doi.org/10.1155/2018/2834109
[42] B. Lang, C. Shang, L.R. Meng, Targeted Silencing of S100A8 Gene by miR-24 to Increase Chemotherapy Sensitivity of Endometrial Carcinoma Cells to Paclitaxel, Med Sci Monit. 22 (2016) 1953-1958.https://doi.org/10.12659/msm.899179